Keryx downgraded
September 08, 2014 at 12:28 PM EDT
FBR Capital downgraded
Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) from a Market Perform
rating to an Underperform rating sending the stock price tumbling $1.55
to $15.46.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.